169 results about "Granulocyte" patented technology

The invention relates to the technical field of artificial intelligence, in particular to a special child disease classification method based on particle-ball cross-granularity knowledge collaborative feature selection. The method comprises the following steps: firstly, providing a cross-granularity knowledge collaboration method based on granules and balls; further designing a fuzzy rough set model based on particle-ball cross-granularity knowledge collaboration to perform feature selection; according to the method, feature knowledge under different granularity levels is mined and coordinated to realize more robust and more efficient feature selection, so that the accuracy, generalization ability and interpretability of a classification model are improved, and a more reliable technical tool is provided for early screening and auxiliary diagnosis of diseases of special children.

The application discloses application of volatile oil of Citrus aurantium in preparation of a medicine for preventing and treating allergic rhinitis. The application proposes that the volatile oil of Citrus aurantium can significantly reduce the levels of mast cell factors IL-1beta and TNF-alpha, and can also significantly reduce the levels of inflammatory factors IL-13 and IL-4 in mice, reduce inflammatory cell infiltration, and reduce eosinophilic granulocyte increase and gland hyperplasia. The application proposes that the volatile oil of Citrus aurantium has great potential as a medicinal and edible raw material for treating allergic rhinitis. The application also proposes that the volatile oil of Citrus aurantium can significantly improve symptoms such as sneezing, runny nose, and nasal itching of mice caused by allergic rhinitis, and the symptoms seriously affect the life of patients.

To provide methods for managing, treating, or preventing an eosinophil or mast cell related disorder and / or one or more symptoms thereof, for example a mast cell related disorder of the nervous system, e.g., central nervous system, for example neuromyelitis optica (NMO), neuromyelitis optica spectrum disorder (NMOSD), multiple sclerosis (MS), and neurofibromatosis (NF).SOLUTION: The present invention provides a method including administering to a subject in need thereof a therapeutically effective amount of an antibody which specifically binds to a KIT receptor tyrosine kinase.SELECTED DRAWING: None

This invention relates to the fields of biomedical technology and biological model construction technology, and discloses an ANCA-associated vasculitis glomerular endothelial cell injury model, its construction method and application, and the application of BACH1 inhibitors. The method includes: (1) activating neutrophils sequentially with tumor necrosis factor α and immunoglobulin G to obtain a culture medium containing activated neutrophils; wherein the immunoglobulin G is immunoglobulin G isolated and purified from the plasma of patients with ANCA-associated vasculitis; (2) co-culturing the culture medium containing activated neutrophils with human glomerular endothelial cells to obtain the cell injury model. The cell injury model provided by this invention can verify the role of neutrophil adhesion characteristics in endothelial cell injury, and at the same time, the cell injury model can better simulate the immune microenvironment of ANCA-associated vasculitis glomerular endothelial cells in vivo.

The application discloses CpG-containing oligodeoxynucleotide (ODN) with the function of regulating the body's immune capacity and application thereof. The oligodeoxynucleotide in the application is different from the design concept of traditional A-type CpG ODN in sequence and structure, embodies the complex drug-making rule and overcomes the problem of traditional A-type CPG in drug-making. The oligodeoxynucleotide has excellent activity of regulating the body's immune function in vitro and in vivo, can stimulate the production of I, II and III type interferons, regulates the Th1 type immune response, and inhibits the Th2 type and Th17 type inflammatory response. Therefore, the oligodeoxynucleotide can prevent and treat allergic diseases caused by Th2 type immune response, including allergic rhinitis, atopic dermatitis, asthma, chronic obstructive pulmonary disease, eosinophil and Th17 related diseases, can prevent and treat the infection and spread of respiratory or non-respiratory pathogenic microorganisms including viruses, bacteria, fungi and parasites, can improve the immune level of the elderly and immunodeficient population, can convert "cold tumor" into "hot tumor", improve the effect of cancer immunotherapy, can prevent and treat central nervous system diseases related to immune dysfunction such as Alzheimer's disease, and can be applied to other diseases related to immune dysfunction.

Embodiments of the instant disclosure relate to intervention and / or treatment of autism spectrum disorder (ASD). Certain embodiments relate to treating a subject having ASD with one or more proinflammatory cytokines. In some embodiments, the one or more proinflammatory cytokines include, but are not limited to, granulocyte-macrophage colony-stimulating factor (GM-CSF) or derivative thereof, or fusion polypeptide thereof, or recombinant thereof. Other embodiments include a mouse model for assessing efficacy of treatment of ASD in humans and other mammals.

The present invention relates to gene therapy agents for the treatment of pulmonary alveolar proteinosis (PAP), particularly autoimmune PAP (aPAP). In particular, the present invention relates to gene therapy vectors which drive transient and / or low-level expression of granulocyte-macrophage colony-stimulating factor (GM-CSF), which provide a therapeutic effect without therapy-associated toxicity. The invention further relates to related products and an animal model of aPAP.

Disclosed herein are embodiments of a method for treating a disease or condition in a subject, comprising administering to the subject, a pyrazole compound according to formula I.The compound may be administered as a composition, such as a spray-dried formulation. The disease or condition may be hidradenitis suppurativa, or a lymphoid neoplasm, and may be chronic myeloid leukemia or chronic myelomonocytic leukemia.

This disclosure relates to RNAi agents capable of inhibiting complement factor B (CFB) gene expression. Pharmaceutical compositions containing CFB RNAi agents and methods of use thereof are also disclosed. The CFB RNAi agents disclosed herein may be conjugated to a targeted ligand containing an N-acetyl-galactosamine ligand to facilitate in vivo delivery to hepatocytes. RNAi agents can be used in methods of treating diseases, disorders, or conditions partially mediated by CFB gene expression, including IgA nephropathy (IgAN), C3 glomerulopathy (C3G), immune complex-mediated membrane proliferative glomerulonephritis (IC-MPGN), lupus nephritis (LN), anti-glomerular basement membrane antibody disease (anti-GBM), ischemia-reperfusion injury and T-cell-mediated rejection in kidney transplantation (TCMR), anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis, age-related macular degeneration (AMD) including early and / or intermediate-stage AMD, geographic atrophy (GA), glaucoma, Doyne honeycomb retinal dystrophy, paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), pre-eclampsia, rheumatoid arthritis (RA), and / or other complement-mediated disorders.

The invention discloses a moisturizing and soothing fermentation composition as well as a preparation method and application thereof. The preparation method of the moisturizing and soothing fermentation composition comprises the following steps: (1) inoculating a fermentation substrate containing centella asiatica and paeonia lactiflora with a seed solution of hirsutella asiatica for fermentation so as to obtain a crude fermentation solution; and (2) carrying out heating treatment and filtering treatment on the crude fermentation liquid to obtain the moisturizing and soothing fermentation composition. The moisturizing and soothing fermentation composition prepared by the invention adopts a mode of extracting and preparing multiple components at the same time, a galactose yeast-like bacterium fermentation product filtrate is prepared, and the moisturizing and soothing fermentation composition also contains a centella asiatica extract and a Chinese herbaceous peony extract; the composition can promote the expression of a paphiopedilum A protein gene, reduce the expression of an IL-6 gene and inhibit zebra fish neutrophile granulocyte aggregation; the moisturizing and soothing effects can be shown from multiple angles.

The invention provides a method for detecting eosinophilic granulocyte peroxidase and application thereof, and relates to the technical field of biological detection.The method comprises the steps that a respiratory tract sample and a sample treatment reagent are mixed, dispersion treatment and centrifugation are conducted, supernatant is taken, and a to-be-detected sample is obtained; carrying out magnetic particle chemiluminescence detection on a to-be-detected sample, and judging the content of eosinophilic granulocyte peroxidase according to a luminescence signal value obtained by detection, the final pH value of the reaction system is 8.0-12.0 according to the detection of a light-emitting signal value; the sample treatment reagent is an aqueous solution containing 0.06-0.12% w / v of a reducing agent. The technical prejudice that the EPX detection is interfered by the peroxidase activity of the EPX in the prior art is overcome; and meanwhile, the mucus is uniformly dispersed through dispersion treatment by virtue of a sample treatment reagent containing a reducing agent, so that high-sensitivity and high-specificity full-automatic detection of the respiratory tract sample EPX is realized on the magnetic particle chemiluminescence platform for the first time.

The invention provides a granulocyte-macrophage colony stimulating factor antibody and application thereof, and belongs to the technical field of biological medicine. A granulocyte-macrophage colony stimulating factor (GM-CSF) antibody or fragment has high affinity, can effectively block GM-CSF / GM-CSF receptor interaction, and has low immunogenicity. The GM-CSF antibody or fragment can be used for preventing and / or treating diseases caused by human GM-CSF or detecting human GM-CSF protein or diagnosing related diseases caused by the human GM-CSF protein.

The present application relates to the field of biological medicine, in particular to a sensitizing agent for constructing a neutrophilic asthma animal model, a construction method and application. The present application uses Haemophilus influenzae outer membrane vesicles and ovalbumin as a sensitizing agent to construct a neutrophilic asthma animal model, and the test results show that the level of neutrophils in the blood and lung lavage fluid of mice is significantly increased compared with the treatment of ovalbumin as a sensitizing agent alone. The constructed mouse neutrophilic asthma model can be used for the research on the mechanism of clinical neutrophilic asthma and the development of neutrophilic asthma drugs.

The present invention relates to the dipeptidyl-peptidase I (DPPI or Cathepsin C) inhibitor of formula (I), which is useful in the prevention and / or treatment of bronchiectasis with certain underlying aetiologies, in the prevention and / or treatment of anti-neutrophil cytoplasmic antibody-associated vasculitis or hidradenitis suppurativa using therapeutically efficacious dosages and to polymorphs of Compound (I) as well as to pharmaceutical compositions comprising Compound (I) and its polymorphs.

The invention discloses nucleotide of fusion protein for coding neutrophil elastase and application of the nucleotide. A nucleotide sequence for coding the fusion protein is as shown in SEQ ID NO. 8; the nucleotide sequence of mRNA (messenger ribonucleic acid) for coding the fusion protein is as shown in SEQ ID NO. 12; the fusion protein comprises an optimized human neutrophil elastase (ELANE) fragment and an optimized human alpha2-macroglobulin (A2M) fragment. The mRNA preparation which is encapsulated by the nano-lipid particles and is used for coding the wild type ELANE can achieve a tumor elimination effect only by complex intratumor injection. According to the mRNA preparation which is encapsulated by the nano-lipid particles and is used for coding the ELANE fusion protein, tumor elimination in a mouse body can be realized only through intramuscular injection administration, the operation is simpler and more convenient, and the mRNA preparation is beneficial to treatment of scattered and tiny tumor focuses in the body.

This invention relates to an efficient particle sphere generation method based on principal component analysis (PCA), belonging to the field of quantum computing. It solves the problem of low data representation efficiency caused by excessive segmentation and noise sensitivity in existing particle sphere algorithms. The technical solution includes: initializing the particle sphere set using a parallel sampling strategy; calculating the splitting gain and setting a threshold; calculating the optimal splitting direction based on the PCA core sample set; splitting the particle spheres along the principal direction and iteratively updating the set. This method achieves efficient data compression, reduces computational complexity, enhances the representation ability of complex geometric structures, and has strong robustness.

This invention relates to a polynucleotide targeting the PML-RARG fusion gene and its applications. The PML-RARG fusion gene is formed by the fusion of exon 6 of the PML gene and exon 4 of the RARG gene. The polynucleotide contains a first sequence configured to hybridize with genomic DNA near the break junction of the PML-RARG fusion gene, the first sequence being GGAGGCAGCGGTGGAGA. This invention provides a polynucleotide targeting a novel subtype of the PML-RARG fusion gene. Based on this polynucleotide, new acute promyelocytic leukemia (APML) detection compositions and gene editing tools can be developed, providing further support for research on the pathogenesis of this subtype of AML and drug development.

The invention relates to an InDel molecular marker related to immune traits of Landaise geese and application of the InDel molecular marker, and belongs to the technical field of molecular markers. The InDel molecular marker provided by the invention is located in a full-length sequence of a CNTFR gene as shown in SEQ ID No.1, and insertion of a single base T exists at the 165833rd site. The InDel molecular marker disclosed by the invention can be used for quickly and accurately distinguishing the high / low ratio of heterophilic granulocytes / lymphocytes of the Landaise geese, has the advantages of simplicity and convenience in operation and reliable result, and provides an effective molecular basis for directional breeding of immune-related traits of the Landaise geese.

The invention relates to the technical field of biological medicine, in particular to DNase I loaded lipidosome and application thereof. The invention provides a bionic long-acting deoxyribonuclease I (DNase I) liposome with free DNA (cfDNA) responsiveness and a dual-targeting function, the liposome is subjected to layered fusion modification through an erythrocyte membrane and a neutrophile granulocyte membrane, a release window is accurately regulated and controlled by utilizing a 4ME-PC proportion, and a liposome drug carrier for cfDNA targeted combination and accurate delivery of an inflammation part is realized. The polypeptide can be used for cfDNA-related inflammatory diseases, and has an important application prospect.

This application belongs to the field of microbial technology, and mainly relates to a strain of *Pediococcus lactis* BPA03 and its applications. *Pediococcus lactis* BPA03 is classified and named *Pediococcus lactis*. Pediococcus acidilactici This *Pediococcus lactis* strain BPA03 was deposited on September 28, 2025, at the China General Microbiological Culture Collection Center (CGMCC), located at No. 3, Courtyard 1, Beichen West Road, Chaoyang District, Beijing, with accession number CGMCC No. 36109. It inhibits skin melanin deposition and improves UV photoaging, suppresses the gene expression levels of immune factors such as IL-1β, IL-6, IL-8, and TNF-α, improves the activities of superoxide dismutase, catalase, and glutathione peroxidase, inhibits vinorelbine-induced neutropenia, and improves the inhibition of immune factor expression induced by vinorelbine, thus exhibiting comprehensive anti-aging effects.

The application discloses a SNP (Single Nucleotide Polymorphism) molecular marker related to an immune character of Landes geese and application thereof, and belongs to the technical field of molecular markers. CNTFR The SNP molecular marker is located in a nucleotide sequence shown in SEQ ID No. 1, and polymorphism exists in any one or more of positions 133334, 165805, 166710 and 174733, corresponding to G>A, C>T, G>A and A>G mutations respectively. The SNP molecular marker provided by the application can realize rapid and accurate identification of the level of the heterophil / lymphocyte ratio of the Landes geese, the method is simple in operation, the result is reliable, the method is suitable for molecular marker assisted breeding of the Landes geese, and the efficiency of breeding for selecting the immune performance is significantly improved.

The present invention provides a pyrimidinone-containing compound, a pharmaceutical composition thereof, and a use thereof. Specifically, disclosed is a compound as shown in formula (I) or a pharmaceutically acceptable salt thereof. The compound of the present invention has strong inhibitory activity against hNE, and the compound or the pharmaceutical composition thereof can be used for treating related diseases caused by an abnormal increase in neutrophil elastase.

The present application relates to the technical field of immune detection, and particularly relates to a granulocyte-macrophage colony stimulating factor determination kit and a detection method thereof. The granulocyte-macrophage colony stimulating factor determination kit comprises GM-CSF magnetic microparticles, GM-CSF luminescent markers, an analysis buffer, a calibrant 1, a calibrant 2, a quality control 1 and a quality control 2. The GM-CSF magnetic microparticles, a sample or the calibrant or the quality control and the analysis buffer are sequentially added, and after incubation and cleaning, the GM-CSF luminescent markers are added for incubation and cleaning, and then the substrate A liquid and the substrate B liquid are sequentially added, and the luminescence intensity is immediately measured, the GM-CSF concentration is calculated according to a calibration curve, the total detection time can be controlled to be about 1 hour, the detection efficiency is greatly improved, and the method can better meet the needs of clinical emergency and high-speed screening. The detection method is simple in operation, fast and accurate in result, and easy to realize automatic high-throughput detection.

Provided is an azacycloalkylcarbonyl cyclic amine compound which is useful as an active ingredient in a pharmaceutical composition for a treatment of a neutrophil associated inflammatory disease. The azacycloalkylcarbonyl cyclic amine compound of the present invention is a compound of Formula (I) or a salt thereof.(in the formula, Ring A represents azacycloalkyl which may have a substituent and may be spiro-fused; Y represents alkyl which may have a substituent, cycloalkyl which may have a substituent, or the like; L represents a nitrogen-containing aromatic heterocycle or the like; Z represents cycloalkyl which may have a substituent, an aromatic hydrocarbon ring which may have a substituent, a non-aromatic heterocycle which may have a substituent, or the like; and m and n each independently represent an integer of 1 or 2.)

This disclosure generally relates to compounds, compositions, and methods for treating various diseases and conditions using therapeutically effective amounts of compounds of formula (I) or formula (II), pharmaceutically acceptable salts thereof, or derivatives thereof. This disclosure generally relates to compounds, compositions, and methods for treating various diseases and conditions, and more specifically, for treating fibrosis and atopic dermatitis (AD), as well as various other diseases and conditions related to neutrophil migration. Embodiments described herein relate to compounds, compositions, and methods for treating and / or preventing fibrosis and various fibrous diseases, disorders, or conditions. TIFF2026521119000072.tif43165

The invention discloses an SNP (Single Nucleotide Polymorphism) molecular marker related to immune traits of Landaise geese and application, and belongs to the technical field of molecular markers. The SNP molecular marker disclosed by the invention is located in a CNTFR gene nucleotide sequence as shown in SEQ ID No.1, and any one or more sites of the 133334 site, the 165805 site, the 166710 site and the 174733 site have polymorphism and are respectively corresponding to Ggt; a, Cgt; t, Ggt; a and Agt; g mutation. The SNP molecular marker provided by the invention can realize rapid and accurate identification of the ratio level of the heterophilic granulocyte / lymphocyte of the Landaise goose, the method is simple and convenient to operate, reliable in result and suitable for molecular marker-assisted breeding of the Landaise goose, and the immune performance breeding efficiency is remarkably improved.

The invention discloses an ABPA animal model building method which comprises the following steps: building an ABPA animal model by injecting a live aspergillus fumigatus spore suspension into an airway, and selecting a mouse for adaptive feeding; a primary sensitization stage; repeating the excitation stage; a live aspergillus fumigatus spore colonization excitation stage; and establishing an evaluation model. The animal model which highly simulates the pathophysiological characteristics of human ABPA is constructed by performing sensitization and excitation in stages and in multiple modes, especially by introducing the key step of lung colonization of live aspergillus fumigatus spores; through increase of serum total IgE and aspergillus fumigatus specific IgE levels, airway eosinophilic granulocyte infiltration and high secretion of mucus, the evaluation model is successfully constructed, and a reliable experimental platform is provided for deep analysis of pathogenesis of diseases.

This invention discloses an antimicrobial peptide, its pharmaceutical composition, and its applications. The invention optimizes the structure of the antimicrobial peptide through deuteration modification technology, significantly enhancing its targeted binding ability to β-1,3-D-glucan synthase. The affinity of this antimicrobial peptide for the aforementioned target is 9-27 times that of the control peptide. In vitro assays show that its minimum inhibitory concentration (MIC) against nine standard Candida strains is consistently 0.002 μg / mL, exhibiting significantly superior activity compared to fluconazole, anidoxurine, and the control peptide. It also exhibits extremely low cytotoxicity against L02 human normal hepatocytes. In in vivo experiments, in a neutropenic mouse model of Candida albicans infection, the antimicrobial peptide at all doses showed superior reduction in renal fungal load compared to anidoxurine and the control peptide. The antimicrobial peptide of this invention combines highly efficient anti-Candida activity, low cytotoxicity, and excellent in vivo efficacy, providing a safe and effective candidate drug for the treatment of drug-resistant candidiasis and possessing good clinical translational value.

Methods of assessing the potency of MSCs to produce anti-inflammatory cytokines in response to a pro-inflammatory stimulus are provided.SOLUTION: The method comprises stimulating MSCs with one or more pro-inflammatory cytokines, such as TNF - α, for a period of time and then identifying and quantifying the production of anti-inflammatory cytokines. MSCs that produce high levels of anti-inflammatory cytokines in response to TNF - α may be used in the treatment of age-related conditions such as age frailty and Alzheimer's disease, and may also be used in the treatment of coronavirus infections. This method shows that TNF - α - induced MSCs reliably secrete several anti-inflammatory cytokines, including IL-1 receptor antagonist (IL-1RA), IL-10, and granulocyte colony-stimulating factor (G-CSF).SELECTED DRAWING: Figure 1

The invention discloses an application of parabacteroides faecalis PM01 in preparation of drugs for preventing or treating inflammatory diseases, and belongs to the technical field of microorganisms. According to the application of the parabacteroides faecalis PM01 in preparation of the medicine for preventing or treating the inflammatory diseases, the parabacteroides faecalis PM01 can inhibit neutrophil and macrophage from gathering towards the inflammation position of the tail fin of zebra fish in an in-vivo inflammation model; the parabacteroides faecalis PM01 can be used for inhibiting the increase of the content of LPS-induced inflammatory factors IL-1beta, IL-6 and TNF-alpha (Tumor Necrosis Factor-alpha); theoretical reference and guidance basis are provided for developing medicines for preventing or treating inflammatory diseases by utilizing the parabacteroides faecalis PM01.